MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
57.40
+0.96
+1.70%
Pre Market: 57.05 -0.35 -0.61% 04:01 10/29 EDT
OPEN
55.84
PREV CLOSE
56.44
HIGH
57.46
LOW
55.66
VOLUME
3
TURNOVER
0
52 WEEK HIGH
59.30
52 WEEK LOW
26.76
MARKET CAP
8.79B
P/E (TTM)
20.91
1D
5D
1M
3M
1Y
5Y
1D
TG Therapeutics Climbed 93% While Profit Fell
Simply Wall St · 1d ago
TG Therapeutics: The Business Is More Attractive Than The Valuation
Seeking Alpha · 1d ago
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and TG Therapeutics (TGTX)
TipRanks · 2d ago
Weekly Report: what happened at TGTX last week (1019-1023)?
Weekly Report · 3d ago
How Early CAR T Results At TG Therapeutics Stock Could Change The Investment Story
Simply Wall St · 4d ago
TG Therapeutics announces Phase 1 data evaluating azer-cel in MS
TipRanks · 5d ago
TG Therapeutics' Initial Data From Its Phase 1 Trial Of Azercabtagene Zapreleucel In Patients With Progressive Multiple Sclerosis Demonstrates 89% Of Evaluable Participants Had Stable Or Improved Disability Scores At Day 90
Benzinga · 5d ago
Notable ETF Outflow Detected - SLYG, PTGX, RHP, TGTX
NASDAQ · 10/21 14:56
More
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.